The serum bone morphogenetic protein-2 level in non-small-cell lung cancer patients

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 582-588

  Choi, Yoon Ji ^a   Kim, Seung Tae ^a   Park, Kyong Hwa ^a   Oh, Sang Cheul ^a   Seo, Jae Hong ^a   Shin, Sang Won ^a   Kim, Jun Suk ^a   Kim, Yeul Hong ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Bone morphogenetic protein 2; Metastatic burden; Non small cell lung cancer; Overall survival; Stage

Indexed keywords

ANTINEOPLASTIC AGENT; BONE MORPHOGENETIC PROTEIN 2; BMP2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; ADENOCARCINOMA; BLOOD; BONE TUMOR; CASE CONTROL STUDY; COMPARATIVE STUDY; FOLLOW UP; LARGE CELL CARCINOMA; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; AGED; BONE MORPHOGENETIC PROTEIN 2; BONE NEOPLASMS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 84866294090     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9852-9     Document Type: Article

References (22)

1. Wozney JM, et al. Novel regulators of bone formation: molecular clones and activities. Science. 1988;242:1528-34.
2. Sampath TK, et al. Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem. 1992;267:20352-62.
3. Hogan BL. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev. 1996;10:1580-94.
4. LI M, Eriksen EF, Bunger C. Bone morphogenetic protein-2 but not bone morphogenetic protein-4 and -6 stimulates chemotactic migration of human osteoblasts, human marrow osteoblasts, and U2-OS cells. Bone. 1996;18:53-7.
5. Massague J. TGFbeta signaling: receptors, transducers, and mad proteins. Cell. 1996;85:947-50.
6. Nissinen L, Pirila L, Heino J. Bone morphogenetic protein-2 is a regulator of cell adhesion. Exp Cell Res. 1997;230:377-85.
7. Hoodless PA, et al. MADR1, a MAD-related protein that functions in BMP2 signaling pathways. Cell. 1996;85:489-500.
8. Derynck R, Zhang Y, Feng XH. Smads: transcriptional activators of TGF-beta responses. Cell. 1998;95:737-40.
9. Cao X, Chen D. The BMP signaling and in vivo bone formation. Gene. 2005;357:1-8.
10. Feeley BT, et al. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res. 2005;20:2189-99.
11. Grijelmo C, et al. Proinvasive activity of BMP-7 through SMAD4/src-independent and ERK/Rac/JNK-dependent signaling pathways in colon cancer cells. Cell Signal. 2007;19:1722-32.
12. Deng H, et al. Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp Cell Res. 2007;313:1033-44.
13. Zhao H, Ayrault O, Zindy F, Kim JH, Roussel MF. Posttranscriptional down-regulation of Atoh1/Math1 by bone morphogenic proteins suppresses medulloblastoma development. Genes Dev. 2008;22:722-7.
14. Langenfeld EM, et al. The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis. 2003;24: 1445-54.
15. Langenfeld EM, Kong Y, Langenfeld J. Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5. Oncogene. 2006;25:685-92.
16. Park Y. Bone morphogenetic protein-2 levels are elevated in the patients with gastric cancer and correlate with disease progression. Med Oncol. 2009;27:1192-9.
17. Raida M, et al. Expression of bone morphogenetic protein 2 in breast cancer cells inhibits hypoxic cell death. Int J Oncol. 2005;26:1465-70.
18. Shepherd TG, Theriault BL, Nachtigal MW. Autocrine BMP4 signalling regulates ID3 proto-oncogene expression in human ovarian cancer cells. Gene. 2008;414:95-105.
19. Jaffee EM, Hruban RH, Canto M, Kern SE. Focus on pancreas cancer. Cancer Cell. 2002;2:25-8.
20. Tang SY. Effect of bone morphogenetic protein-2 on the expression of membrane Type 1-matrix metalloproteinase in human A549 lung carcinoma cells. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2008;33:634-7.
21. Hou CH, Hsiao YC, Fong YC, Tang CH. Bone morphogenetic protein-2 enhances the motility of chondrosarcoma cells via activation of matrix metalloproteinase-13. Bone. 2009;44:233-42.
22. Kang MH, et al. Inhibition of PI3 kinase/Akt pathway is required for BMP2-induced EMT and invasion. Oncol Rep. 2009;22: 525-34.